Year All20242023202220212020 Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity Read More Feb 20, 2024 Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials Read More Feb 01, 2024 Fractyl Health Announces Pricing of Initial Public Offering Read More Jan 05, 2024 Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform Read More
Mar 12, 2024 Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Feb 20, 2024 Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
Jan 05, 2024 Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in it's Rejuva® GLP-1 Gene Therapy Platform